Side effects across medicines
Medicines whose labels list febrile neutropenia
121 medicines have an FDA label that names febrile neutropenia in its boxed warning, warnings, adverse reactions, trial table, patient leaflet or Drug Facts “stop use” warning (of the labels PlainMeds reads: each medicine's quoted label and up to eight more, by route and wording). Among them, the most FAERS reports of febrile neutropenia name cyclophosphamide (14,530), rituximab (8,037) and paclitaxel (3,717), through July 30, 2026. A label lists what its studies and reports found, and a report does not show that a medicine caused the event.
Check it at the source: the FDA FAERS public dashboard; FDA labels on DailyMed.
Which medicines' labels list febrile neutropenia?
Ordered by where the label names it, the boxed warning first, then by FAERS reports. A medicine whose own indications name it, because it treats it, is not counted.
| Medicine | Where a label names it | FAERS reports of febrile neutropenia |
|---|---|---|
| Obinutuzumab | warnings and precautions | 1,042 |
| Blinatumomab | warnings and precautions | 307 |
| Cabazitaxel | warnings and precautions | 248 |
| Isatuximab | warnings and precautions (subcutaneous label) | 149 |
| Aflibercept | warnings and precautions (intravenous label) | 46 |
| Abemaciclib | warnings and precautions | none in the top 1,000 |
| Hyaluronidase and trastuzumab | warnings and precautions | none in the top 1,000 |
| Lurbinectedin | warnings and precautions | none in the top 1,000 |
| Mosunetuzumab | warnings and precautions (intravenous label) | none in the top 1,000 |
| Sonrotoclax | warnings and precautions | none in the top 1,000 |
| Tarlatamab-dlle | warnings and precautions | none in the top 1,000 |
| Cyclophosphamide | adverse reactions | 14,530 |
| Rituximab | adverse reactions | 8,037 |
| Paclitaxel | adverse reactions | 3,717 |
| Venetoclax | adverse reactions | 3,114 |
| Docetaxel | adverse reactions | 3,075 |
| Azacitidine | adverse reactions | 2,963 |
| Lenalidomide | adverse reactions | 2,453 |
| Bevacizumab | adverse reactions | 2,169 |
| Gemcitabine | adverse reactions | 1,835 |
| Oxaliplatin | adverse reactions | 1,820 |
| Pembrolizumab | adverse reactions | 1,587 |
| Pegaspargase | adverse reactions | 1,584 |
| Trastuzumab | adverse reactions | 1,555 |
| Bortezomib | adverse reactions | 1,412 |
| Melphalan | adverse reactions | 1,316 |
| Pemetrexed | adverse reactions | 1,240 |
| Aprepitant | adverse reactions | 1,076 |
| Posaconazole | adverse reactions (intravenous label) | 1,072 |
| Atezolizumab | adverse reactions | 952 |
| Busulfan | adverse reactions | 863 |
| Fosaprepitant | adverse reactions | 819 |
| Bendamustine | adverse reactions | 797 |
| Brentuximab vedotin | adverse reactions | 758 |
| Pertuzumab | adverse reactions | 752 |
| Pomalidomide | adverse reactions | 738 |
| Gemtuzumab ozogamicin | adverse reactions | 697 |
| Polatuzumab vedotin | adverse reactions | 529 |
| Cytarabine and daunorubicin | adverse reactions | 502 |
| Decitabine | adverse reactions | 455 |
| Thalidomide | adverse reactions | 448 |
| Topotecan | adverse reactions | 426 |
| Micafungin | adverse reactions | 424 |
| Carfilzomib | adverse reactions | 419 |
| Palbociclib | adverse reactions | 415 |
| Vinorelbine | adverse reactions | 371 |
| Epirubicin | adverse reactions | 368 |
| Valganciclovir | adverse reactions | 342 |
| Eribulin | adverse reactions | 330 |
| Lapine t-lymphocyte immune globulin | adverse reactions | 327 |
| Durvalumab | adverse reactions | 315 |
| Clofarabine | adverse reactions | 270 |
| Inotuzumab ozogamicin | adverse reactions | 265 |
| Ramucirumab | adverse reactions | 262 |
| Dasatinib | adverse reactions | 231 |
| Cladribine | adverse reactions (intravenous label) | 215 |
| Sacituzumab govitecan | adverse reactions | 203 |
| Dactinomycin | adverse reactions | 192 |
| Caspofungin | adverse reactions | 168 |
| Trabectedin | adverse reactions | 161 |
| Fulvestrant | adverse reactions | 146 |
| Trastuzumab deruxtecan | adverse reactions | 139 |
| Ribociclib | adverse reactions | 127 |
| Glofitamab | adverse reactions | 103 |
| Ponatinib | adverse reactions | 96 |
| Treosulfan | adverse reactions | 96 |
| Ibritumomab tiuxetan | adverse reactions | 94 |
| Olaparib | adverse reactions | 90 |
| Crizotinib | adverse reactions | 88 |
| Tremelimumab | adverse reactions | 87 |
| Nilotinib | adverse reactions | 85 |
| Midostaurin | adverse reactions | 78 |
| Nelarabine | adverse reactions | 75 |
| Tipiracil and trifluridine | adverse reactions | 74 |
| Glasdegib | adverse reactions | 69 |
| Acalabrutinib | adverse reactions | 68 |
| Talazoparib | adverse reactions | 68 |
| Rucaparib camsylate | adverse reactions | 66 |
| Darolutamide | adverse reactions | 62 |
| Aldesleukin | adverse reactions | 51 |
| Anidulafungin | adverse reactions | 49 |
| Ixabepilone | adverse reactions | 49 |
| Niraparib | adverse reactions | 47 |
| Pentostatin | adverse reactions | 47 |
| Cedazuridine and decitabine | adverse reactions | 37 |
| Quizartinib | adverse reactions | 33 |
| Belimumab | adverse reactions | 32 |
| Arsenic trioxide | adverse reactions | 31 |
| Asparaginase | adverse reactions | 25 |
| Encorafenib | adverse reactions | 25 |
| Abiraterone and niraparib | adverse reactions | none in the top 1,000 |
| Asciminib | adverse reactions | none in the top 1,000 |
| Atezolizumab and hyaluronidase | adverse reactions | none in the top 1,000 |
| Berahyaluronidase alfa and pembrolizumab | adverse reactions | none in the top 1,000 |
| Bevacizumab-maly | adverse reactions | none in the top 1,000 |
| Daratumumab | adverse reactions | none in the top 1,000 |
| Elranatamab | adverse reactions | none in the top 1,000 |
| Epcoritamab | adverse reactions | none in the top 1,000 |
| Etuvetidigene autotemcel | adverse reactions | none in the top 1,000 |
| Fostamatinib | adverse reactions | none in the top 1,000 |
| Gilteritinib | adverse reactions | none in the top 1,000 |
| Hyaluronidase and pertuzumab and trastuzumab | adverse reactions | none in the top 1,000 |
| Hyaluronidase and rituximab | adverse reactions | none in the top 1,000 |
| Iberdomide | adverse reactions | none in the top 1,000 |
| Imetelstat | adverse reactions | none in the top 1,000 |
| Interferon gamma 1b | adverse reactions | none in the top 1,000 |
| Loncastuximab tesirine | adverse reactions | none in the top 1,000 |
| Margetuximab | adverse reactions | none in the top 1,000 |
| Pirtobrutinib | adverse reactions | none in the top 1,000 |
| Pivekimab sunirine | adverse reactions | none in the top 1,000 |
| Pralatrexate | adverse reactions | none in the top 1,000 |
| Relacorilant | adverse reactions | none in the top 1,000 |
| Revumenib | adverse reactions | none in the top 1,000 |
| Tafasitamab | adverse reactions | none in the top 1,000 |
| Tagraxofusp | adverse reactions | none in the top 1,000 |
| Teclistamab | adverse reactions | none in the top 1,000 |
| Trastuzumab-strf | adverse reactions | none in the top 1,000 |
| Trilaciclib | adverse reactions | none in the top 1,000 |
| Zanubrutinib | adverse reactions | none in the top 1,000 |
| Ziftomenib | adverse reactions | none in the top 1,000 |
| Zolbetuximab | adverse reactions | none in the top 1,000 |
Source: FDA drug labels via openFDA, read October 8, 2026; FAERS via openFDA, reports through July 30, 2026
Which of them have the most febrile neutropenia reports in FAERS?
Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; MedDRA preferred term “Febrile Neutropenia”
What next?
- Side effects across medicines
- every reaction on PlainMeds
- Report a side effect to the FDA
- MedWatch